Dual-Phase Dual-Energy CT in Patients Treated with Erlotinib for Advanced Non-Small Cell Lung Cancer: Possible Benefits of Iodine Quantification in Response Assessment
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
26563350
DOI
10.1007/s00330-015-4092-6
PII: 10.1007/s00330-015-4092-6
Knihovny.cz E-zdroje
- Klíčová slova
- Dual-energy CT, Iodine contrast medium, Lung cancer, Targeted molecular therapy, Therapy response,
- MeSH
- erlotinib terapeutické užití MeSH
- jod MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- lymfatické uzliny diagnostické zobrazování MeSH
- nádory plic farmakoterapie patologie MeSH
- nemalobuněčný karcinom plic diagnóza farmakoterapie sekundární MeSH
- počítačová rentgenová tomografie metody MeSH
- pozitronová emisní tomografie metody MeSH
- protinádorové látky terapeutické užití MeSH
- reprodukovatelnost výsledků MeSH
- senioři MeSH
- staging nádorů * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- erlotinib MeSH
- jod MeSH
- protinádorové látky MeSH
OBJECTIVES: To investigate the relationship of dual-phase dual-energy CT (DE-CT) and tumour size in the evaluation of the response to anti-EGFR therapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Dual-phase DE-CT was performed in 31 patients with NSCLC before the onset of anti-EGFR (erlotinib) therapy and as follow-up (mean 8 weeks). Iodine uptake (IU; mg/mL) was quantified using prototype software in arterial and venous phases; arterial enhancement fraction (AEF) was calculated. The change of IU before and after therapy onset was compared with anatomical evaluation in maximal transverse diameter and volume (responders vs. non-responders). RESULTS: A significant decrease of IU in venous phase was proved in responders according to all anatomical parameters (p=0.002-0.016). In groups of non-responders, a significant change of IU was not proved with variable trends of development. The most significant change was observed using the anatomical parameter of volume (cut-off 73 %). A significant difference of percentage change in AEF was proved between responding and non-responders (p=0.019-0.043). CONCLUSION: Dual-phase DE-CT with iodine uptake quantification is a feasible method with potential benefit in advanced assessment of anti-EGFR therapy response. We demonstrated a decrease in vascularization in the responding primary tumours and non-significant variable development of vascularization in non-responding tumours. KEY POINTS: • Dual-phase DE-CT is feasible for vascularization assessment of NSCLC with anti-EGFR therapy. • There was a significant decrease of iodine uptake in responding tumours. • There was a non-significant and variable development in non-responding tumours. • There was significant difference of AEF percentage change between responders and non-responders.
Zobrazit více v PubMed
Eur J Radiol. 2012 Mar;81(3):e398-405 PubMed
Radiology. 2005 Sep;236(3):1011-9 PubMed
Future Oncol. 2014 Oct;10(13):2081-96 PubMed
Future Oncol. 2015;11(4):591-606 PubMed
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):56-61 PubMed
Front Oncol. 2014 Jun 27;4:157 PubMed
Eur Radiol. 2014 Apr;24(4):930-9 PubMed
Eur Radiol. 2014 Mar;24(3):574-80 PubMed
Radiology. 2014 Apr;271(1):6-27 PubMed
Cancer Chemother Pharmacol. 2014 Feb;73(2):299-307 PubMed
J Thorac Dis. 2014 Apr;6(4):319-27 PubMed
Cancer Imaging. 2013 Mar 06;13:81-91 PubMed
Eur Radiol. 2012 Jan;22(1):93-103 PubMed
Eur Radiol. 2012 Jul;22(7):1430-41 PubMed
Radiother Oncol. 2013 Oct;109 (1):65-70 PubMed
Radiology. 2009 Feb;250(2):425-434 PubMed
Eur J Cancer. 2009 Jan;45(2):228-47 PubMed
Radiology. 2006 May;239(2):547-53 PubMed
Eur Radiol. 2014 Aug;24(8):1896-905 PubMed
Eur Radiol. 2013 Aug;23 (8):2127-36 PubMed
Eur Radiol. 2007 Jun;17(6):1510-7 PubMed
Eur Radiol. 2014 Aug;24(8):1981-8 PubMed
N Engl J Med. 2005 Jul 14;353(2):123-32 PubMed
Eur J Radiol. 2011 Dec;80(3):e278-83 PubMed
Invest Radiol. 2012 Jan;47(1):2-4 PubMed
J Nucl Med. 2012 Apr;53(4):521-9 PubMed
Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S30-51 PubMed
Korean J Radiol. 2012 Nov-Dec;13(6):702-10 PubMed
Eur Radiol. 2010 Dec;20(12 ):2890-8 PubMed
Lancet Oncol. 2010 Jun;11(6):521-9 PubMed
